Clinical trial · Interventional
VELCADE,Rituximab,Cyclophosphamide and Decadron
Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma
NCT00413959CI-TRIAL-00034959VRCDterminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, B-Cell | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Decadron | Drug | Dexamethasone | ALIAS |
| Rituximab | Drug | Rituximab | ALIAS |
| VELCADE® | Drug | Bortezomib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Velcade, Rituximab,Cyclophosphamide & Decadron
- description
- Velcade 375 mg/m\^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
- interventionNames
- Drug: VELCADE®
- Drug: Rituximab
- Drug: Cyclophosphamide
- Drug: Decadron
Primary outcomes (1)
- measure
- Overall Response Rate Using This Regimen in Patients With Low-grade B-Cell Non-Hodgkin's Lymphoma.
- timeFrame
- 4 years
- description
- Percentage of complete responders plus percentage of partial responders equals overall response rate.
Secondary outcomes (1)
- measure
- Overall Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Small Lymphocytic Lymphoma * Follicular Cell Lymphoma (grades I and II) * Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant * Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia * Marginal Zone Lymphoma * MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation. * Adequate bone marrow function, renal function, and hepatic function as outlined in details below. * ECOG performance status of 0, 1, or 2 * Able to read, understand, and sign an IRB approved informed consent Exclusion Criteria: * Known HIV positive status * Known CNS involvement * Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.
References
Publications (0)
Data not yet available
No reference posted for this study.